SCIENTURE HOLDINGS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
SCIENTURE HOLDINGS, INC. (SCNX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$2.38 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2026-03-30
- SCIENTURE HOLDINGS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2024-12-31 was $0.00.
- SCIENTURE HOLDINGS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2024-09-30 was $120.98K, a 16.23% decline year-over-year.
- SCIENTURE HOLDINGS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2024-06-30 was $0.00.
- SCIENTURE HOLDINGS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2024-03-31 was -$2.50M.
- SCIENTURE HOLDINGS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2024 was -$2.38M.
- SCIENTURE HOLDINGS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2023 was -$344.45K, a 46088.52% decline from fiscal 2022.
- SCIENTURE HOLDINGS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2022 was $749.00.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $120.98K derived: sum of 2 quarters · filed 2026-03-30 | $120.98K derived: sum of 3 quarters · filed 2026-03-30 | -$2.38M 10-K · filed 2026-03-30 |
| 2024-09-30 | $120.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $120.98K derived: sum of 2 quarters · filed 2025-11-12 | -$2.38M 10-Q · filed 2025-11-12 | -$2.73M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$2.50M 10-Q · filed 2025-08-12 | -$2.85M derived: sum of 3 quarters · filed 2025-08-12 | -$2.71M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$2.50M 10-Q · filed 2025-05-12 | -$2.85M derived: sum of 2 quarters · filed 2025-05-12 | -$2.71M derived: sum of 3 quarters · filed 2025-05-12 | -$2.76M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$350.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$205.58K derived: sum of 2 quarters · filed 2025-03-26 | -$257.38K derived: sum of 3 quarters · filed 2025-03-26 | -$344.45K 10-K · filed 2025-03-26 |
| 2023-09-30 | $144.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $92.62K derived: sum of 2 quarters · filed 2024-11-06 | $5.55K 10-Q · filed 2024-11-06 | $319.20K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$51.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$138.88K 10-Q · filed 2024-08-09 | $174.78K derived: sum of 3 quarters · filed 2024-08-09 | $119.05K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$87.07K 10-Q · filed 2024-06-26 | $226.58K derived: sum of 2 quarters · filed 2024-06-26 | $170.85K derived: sum of 3 quarters · filed 2024-06-26 | -$109.32K derived: sum of 4 quarters · filed 2024-06-26 |
| 2022-12-31 | $313.65K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-22 | $257.92K derived: sum of 2 quarters · filed 2024-04-22 | -$22.25K derived: sum of 3 quarters · filed 2024-04-22 | $749.00 10-K · filed 2024-04-22 |
| 2022-09-30 | -$55.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-16 | -$335.90K derived: sum of 2 quarters · filed 2024-01-16 | -$312.90K 10-Q · filed 2024-01-16 | |
| 2022-06-30 | -$280.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-18 | -$257.17K 10-Q · filed 2023-08-18 | ||
| 2022-03-31 | $23.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |